Ari Maizel's most recent trade in Axsome Therapeutics Inc was a trade of 7,816 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 21, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 7,816 | 7,816 | - | - | Employee Stock Option (Right to Buy) | |
Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 7,740 | 7,740 | - | - | Performance Stock Units | |
Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 7,740 | 7,740 | - | - | Restricted Stock Units |